null

null

null

null

null

null

null

null

null

Pre-bankruptcy high leverage; ~$130M in debt with minimal revenue; debt-to-equity ratio deeply negative by 2019

Variable-rate credit facility exposure modest; primary risk was equity dilution and covenant breach, not rate fluctuation

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API-producing fermentation manufacturing in China (Lonza/CMO dependency) and Indian API sourcing for plazomicin precursors

Minimal international revenue at bankruptcy; EU regulatory approval pending, near-zero forex exposure at time of collapse

Predominantly US-focused; no material international revenue streams; sovereign currency devaluation risk effectively negligible

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single CMO (contract manufacturer) for plazomicin represented non-substitutable critical path; high lock-in, >30% input cost

Pharmaceutical drug developer and commercial-stage biotech; asset-based, not cloud-dependent SaaS

Cloud infrastructure termination risk low; primary operational dependency on lab systems, FDA portals, and CRM, not AWS-scale platforms

API coupling risk minimal; no external API revenue model; internal systems were standard pharma commercial stack

Revenue from drug sales fails Howey Test; equity financing via common stock carries standard securities risk, not Howey-triggering structure

Very High

Limited GDPR/CCPA exposure; patient data governed by HIPAA; small commercial footprint reduced cross-border data transfer risk

Low antitrust risk; plazomicin had minimal market share; no dominant position in any antibiotic segment achieved before bankruptcy

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Transactional drug sales ~100%; no subscription or multi-year contract revenue; hospital formulary orders were episodic purchases

Per-unit drug sales to hospital GPOs and specialty distributors; single-product revenue stream (plazomicin/ZEMDRI)

WAC ~$38,000/course; pricing set above competitor aminoglycosides but challenged by payer pushback and limited formulary adoption

Weak; payers resisted premium pricing for last-resort antibiotic with limited Phase 3 mortality benefit vs. colistin comparator

Targeted 70%+ gross margin typical for specialty pharma; actual margins crushed by low volume and high manufacturing fixed costs

No free-rider problem; access controlled via prescription and payer authorization; issue was demand generation failure, not leakage

Headcount-linear; built ~200-person commercial sales force for single product, creating unsustainable fixed cost base vs. revenue

High marginal cost; each additional hospital account required dedicated MSL and sales rep; no scalable digital channel

Not applicable; no franchise model; direct sales force model with standard pharma compliance (PDMA, Anti-Kickback Statute)

At 10x scale, CAC economics remain poor; hospital formulary selling requires relationship-intensive process regardless of volume

No network effects; antibiotic adoption is clinician-driven, infection-driven, and episodic; zero demand-side scale benefits

AI displacement risk low in 2019 context; core value in FDA approval and clinical data, not AI-displaceable workflow

Moderate resistance theoretically (infectious disease is non-discretionary), but payer cost-cutting amplified formulary exclusion risk

Hospital systems and academic medical centers treating CRE/MDR gram-negative bacterial infections

Specialty infectious disease physicians and antimicrobial stewardship programs within large hospital networks

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capex outsourced to CMOs; internal spend was SG&A-heavy commercial buildout; no legacy-to-future infrastructure reallocation

1070154

AKAO (delisted 2019); traded at steep discount reflecting commercial failure, covenant breach risk, and single-product pipeline concentration